UY31212A1 - PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A BENZODIAZEPINIC AGENT - Google Patents
PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A BENZODIAZEPINIC AGENTInfo
- Publication number
- UY31212A1 UY31212A1 UY31212A UY31212A UY31212A1 UY 31212 A1 UY31212 A1 UY 31212A1 UY 31212 A UY31212 A UY 31212A UY 31212 A UY31212 A UY 31212A UY 31212 A1 UY31212 A1 UY 31212A1
- Authority
- UY
- Uruguay
- Prior art keywords
- agent
- pharmaceutical composition
- benzodiazepinic
- benzisoxazolic
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención esta relacionada con una composición farmacéutica compuesta por la combinación sinérgica de un agente derivado benzisoxazólico, como lo es el principio activo: Risperidona y un agente benzodiazepínico, como lo es el principio activo: Clonazepam, los cuales se encuentran formulados en una sola unidad de dosificación para ser administrada por vía oral en forma de cápsulas o tabletas, misma que está indicada para el control y tratamiento de enfermedades tales como: trastornos psicóticos y patologías relacionadas.The present invention is related to a pharmaceutical composition composed of the synergistic combination of a benzisoxazole derivative agent, such as the active substance: Risperidone and a benzodiazepineic agent, such as the active substance: Clonazepam, which are formulated in a single Dosing unit to be administered orally in the form of capsules or tablets, which is indicated for the control and treatment of diseases such as: psychotic disorders and related pathologies.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2007008323A MX2007008323A (en) | 2007-07-06 | 2007-07-06 | Pharmaceutical composition comprising the combination of a benzisoxazolic derived agent and a benzodiazepinic agent. |
Publications (1)
Publication Number | Publication Date |
---|---|
UY31212A1 true UY31212A1 (en) | 2009-01-05 |
Family
ID=40228771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY31212A UY31212A1 (en) | 2007-07-06 | 2008-07-07 | PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A BENZODIAZEPINIC AGENT |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR067465A1 (en) |
MX (1) | MX2007008323A (en) |
UY (1) | UY31212A1 (en) |
WO (1) | WO2009008695A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE112015005205T5 (en) | 2014-11-18 | 2017-08-17 | Ntn Corporation | Roller bearing support and method of manufacturing the holder |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05012317A (en) * | 2003-05-16 | 2006-01-30 | Pfizer Prod Inc | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines. |
-
2007
- 2007-07-06 MX MX2007008323A patent/MX2007008323A/en not_active Application Discontinuation
-
2008
- 2008-07-04 WO PCT/MX2008/000084 patent/WO2009008695A1/en active Application Filing
- 2008-07-07 AR ARP080102923A patent/AR067465A1/en unknown
- 2008-07-07 UY UY31212A patent/UY31212A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR067465A1 (en) | 2009-10-14 |
MX2007008323A (en) | 2009-02-18 |
WO2009008695A1 (en) | 2009-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR093247A1 (en) | PROFILACTIC AND / OR THERAPEUTIC AGENT FOR BEHAVIOR AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL ILLNESS CONTAINING BREXPIPRAZOL OR SALTS OF THE SAME | |
MX2009003372A (en) | Non-mucoadhesive film dosage forms. | |
ECSP10010224A (en) | LUTEINIZING HORMONE LIQUID FORMULATIONS (LH). | |
BR112013032122A2 (en) | modified release of 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoromethyl) phenyl] benzamide solubilized using organic acids | |
AR091351A1 (en) | BROMOCRIPTINE FORMULATIONS, METHOD FOR IMPROVING GLUCEMIC CONTROL AND METHOD FOR MANUFACTURING | |
BR112014014795A2 (en) | immediate release multi-unit pellet system | |
PE20040973A1 (en) | COMPOSITIONS OF ANTI-HISTAMINES, DECONGESTIVES AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | |
ECSP099734A (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTI-CONVULSIVING AGENT | |
AR083095A1 (en) | APREPITANT L-PROLINA AND PHARMACEUTICAL COMPOSITION CO-CRYSTAL | |
CO6270220A2 (en) | PHARMACEUTICAL COMPOSITIONS UNDERSTANDING THE COMBINATION OF A NON-STEROID ANTIINFLAMOTORY AGENT AND AN INHIBITING AGENT OF THE XANTINO OXIDASE USEFUL FOR THE CONTROL AND TREATMENT OF THE DROP DROPPED ARTHRITIS AND RELATED DISEASES | |
UY31212A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A BENZODIAZEPINIC AGENT | |
AR074246A1 (en) | DERIVATIVES OF 1-AMINO-ALQUILCICLOHEXANO FOR THE TREATMENT OF SOIL DISORDERS | |
BR112012020415A2 (en) | pharmaceutical composition for the prevention or treatment of osteoarthritis | |
UY31230A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN ANTI-CONVULSION AGENT AND A BENZODIAZEPINIC AGENT, INDICATED FOR THE CONTROL AND TREATMENT OF CONVULSIVE DISORDERS AND EPILEPTIC SYNDROMES. | |
PE20090316A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING THE COMBINATION OF AN ANTIMICROBIAL AGENT AND AN ANTIOXIDANT AGENT FOR THE TREATMENT OF URINARY INFECTIONS | |
UY31231A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A REVERSIBLE INHIBITING AGENT OF CHOLINESTERASE ENZYME, INDICATED FOR THE CONTROL AND TREATMENT OF PSYCHOTIC DISORDERS AND DEMENCIES. | |
GT200900275A (en) | SYNERGIC PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF AN INHIBITOR OF ENZYME 5 A-REDUCTASE AND AN ANTAGONIST OF RECEIVERS 1 A-ANDRENÉRGICOS. | |
UY31248A1 (en) | PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF AN ANTIANDROGEN AGENT, A SYNTHETIC STERETIC STROGEN AGENT AND VITAMINAL AGENTS, USEFUL FOR THE CONTROL AND TREATMENT OF LATE ACNE IN WOMEN | |
PE20090725A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING THE COMBINATION OF AN ANTI-ARTHRITIC AGENT AND AN INTERLEUKIN-1 INHIBITING AGENT, USEFUL FOR THE CONTROL AND TREATMENT OF OSTEOARTHROSIS AND RELATED DISEASES | |
UY31213A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING THE COMBINATION OF AN ANTIDEPRESSIVE AGENT AND AN ANSIOLITIC AGENT FOR THE CONTROL AND TREATMENT OF DEPRESSIVE DISORDERS | |
MX2016006375A (en) | A combination of dosage units for use in the treatment of pre-term labour condition. | |
AR071736A1 (en) | PHARMACEUTICAL COMPOSITION COMPOSED BY THE COMBINATION OF VARIOUS ANTISPASMODIC AGENTS AND AN NON-STEROID ANTI-INFLAMMATORY AGENT, USEFUL FOR THE CONTROL AND TREATMENT OF RENAL COLICO AND INFLAMMATION | |
GT200900316A (en) | PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF AN INHIBITING AGENT OF THE HMG-COA REDUCTASE ENZYME AND AN INHIBITING AGENT OF THE GASTROINTESTINAL ENZYME LIPASE | |
PE20091200A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING A COMBINATION OF ACEMETACIN, METHOCARBAMOL AND DIACEREIN | |
CO6241103A2 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTI-CONVULSIVING AGENT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20140924 |